PMID- 18796298
OWN - NLM
STAT- MEDLINE
DCOM- 20090121
LR  - 20221207
IS  - 0009-8981 (Print)
IS  - 0009-8981 (Linking)
VI  - 398
IP  - 1-2
DP  - 2008 Dec
TI  - Polymorphisms in advanced glycosylation end product-specific receptor (AGER) 
      gene, insulin resistance, and type 2 diabetes mellitus.
PG  - 95-8
LID - 10.1016/j.cca.2008.08.020 [doi]
AB  - BACKGROUND: Variants in the advanced glycosylation end product-specific receptor 
      (AGER) gene have been associated with diabetic vasculopathy, however their role 
      in the pathogenesis of insulin resistance and type 2 diabetes mellitus (T2DM) are 
      uncertain. We investigated the relationship of 3 polymorphisms (rs1800625, 
      rs1800624 and rs2070600) in the AGER gene and their haplotypes with T2DM as well 
      as insulin resistance. METHODS: A case-control study from community-based 
      population sample of the Boston metropolitan area was performed in 637 diabetic 
      patients and 596 controls (non-diabetic). The relationships between genotypes and 
      T2DM were evaluated by linear and logistic regression models. Associations with 
      insulin resistance [using corrected insulin response (CIR-30), insulin 
      sensitivity index (ISI-120) and oral glucose tolerance test] were also examined 
      among controls. RESULTS: We found no consistent association between prevalent 
      type 2 diabetes mellitus, and "insulin indices" (CIR-30, ISI-120 and oral glucose 
      tolerance test) and the AGER polymorphisms. The A allele in the rs1800624 was 
      modestly associated with a progressive decrease in CIR-30 levels only among Black 
      controls (p=0.03). CONCLUSIONS: A suggestive association between the A allele in 
      the rs1800624 and CIR-30 levels was found. Further large and multiethnic studies 
      should be performed to clarify these relationships.
FAU - Goulart, A C
AU  - Goulart AC
AD  - Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical 
      School, Boston, MA, United States. agoulart@partners.org
FAU - Germer, S
AU  - Germer S
FAU - Rexrode, K M
AU  - Rexrode KM
FAU - Martin, M
AU  - Martin M
FAU - Zee, R Y L
AU  - Zee RY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080903
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, Immunologic)
SB  - IM
MH  - Alleles
MH  - Black People
MH  - Body Mass Index
MH  - Boston/epidemiology
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/epidemiology/*genetics
MH  - Female
MH  - Glucose Tolerance Test
MH  - Haplotypes
MH  - Humans
MH  - Insulin Resistance/*genetics
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Polymorphism, Genetic/*genetics
MH  - Receptor for Advanced Glycation End Products
MH  - Receptors, Immunologic/*genetics
MH  - Regression Analysis
MH  - White People
EDAT- 2008/09/18 09:00
MHDA- 2009/01/22 09:00
CRDT- 2008/09/18 09:00
PHST- 2008/05/22 00:00 [received]
PHST- 2008/08/15 00:00 [revised]
PHST- 2008/08/22 00:00 [accepted]
PHST- 2008/09/18 09:00 [pubmed]
PHST- 2009/01/22 09:00 [medline]
PHST- 2008/09/18 09:00 [entrez]
AID - S0009-8981(08)00430-0 [pii]
AID - 10.1016/j.cca.2008.08.020 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2008 Dec;398(1-2):95-8. doi: 10.1016/j.cca.2008.08.020. Epub 2008 
      Sep 3.